<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="358">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749160</url>
  </required_header>
  <id_info>
    <org_study_id>20CH191</org_study_id>
    <secondary_id>2020-A02737-32</secondary_id>
    <nct_id>NCT04749160</nct_id>
  </id_info>
  <brief_title>Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T</brief_title>
  <acronym>SMART²T</acronym>
  <official_title>Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      European recommendations indicate to start a conventional synthetic disease modifying&#xD;
      antirheumatic drug (csDMARD) as soon as possible to reach the remission in early RA or low&#xD;
      disease activity in established RA. If the target is not achieved with the first csDMARD and&#xD;
      in presence of poor prognostic, addition of a biologic (b)DMARD or a targeted synthetic&#xD;
      (ts)DMARD should be considered . Nevertheless, as many as one-third of patients have&#xD;
      persistent disease activity and insufficient (inadequate) response to a first b/tsDMARD&#xD;
      according to international recommendations. This relatively long time (3 to 6 months) between&#xD;
      treatment initiation and determination of individual clinical response represents:&#xD;
&#xD;
        -  a risk for the patient who could be usually exposed to potential side effects,&#xD;
&#xD;
        -  a loss of chance for the patient who will not receive an adequate treatment during the&#xD;
           most favorable period and thus may develop irreversible lesions&#xD;
&#xD;
        -  a cost for the healthcare system, especially in terms of expensive drug reimbursements,&#xD;
           notwithstanding the increasing use of biosimilars.&#xD;
&#xD;
      Despite 20 years of research, no biomarker or no way are available in the daily practice to&#xD;
      predict disease activity and the non-response to a b/tDMARD [11]. Thus exploration of a new&#xD;
      approach is totally in purpose.&#xD;
&#xD;
      The aim of this project is to benefit from the declarative PRO (Patient Reported Outcomes),&#xD;
      the physical activity and sleep quality to predict the individual clinical response to the&#xD;
      b/tsDMARDs&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>physical activities</measure>
    <time_frame>3 months</time_frame>
    <description>Physical activities including number of steps per day and per hour. Physical activities are measured with a smart watch (with accelerometer without location data)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>physical activities and sleep quality</measure>
    <time_frame>3 months</time_frame>
    <description>sleep quality data including time of sleeping (number of hours). sleep quality is measured with a smart watch (with accelerometer without location data)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapid-3 score</measure>
    <time_frame>3 months</time_frame>
    <description>Routine Assessment of Patient Index Data (Rapid-3) score is a self-administered score demonstrated capacity to capture Rheumatoid arthritis activity (score : 0,0 to 30,0).&#xD;
Remission : score 0- 3,0 Low Disease Activity : score 3,1- 6,0 Moderate Disease Activity : score 6,1 - 12,0 High Disease Activity : score 12,1 - 30</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis (RA) with connected device</arm_group_label>
    <description>RA with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD.&#xD;
the physical activity and sleep quality measured with connected device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Connected device</intervention_name>
    <description>Connected device is a smart watch (with accelerometer without location data).</description>
    <arm_group_label>Rheumatoid arthritis (RA) with connected device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        RA patient with DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time&#xD;
        a bDMARD or a tsDMARD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adult patient (over 18 years old)&#xD;
&#xD;
          -  RA according to ACR/EULAR 2010 criteria since less than 6 months&#xD;
&#xD;
          -  DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or&#xD;
             a tsDMARD&#xD;
&#xD;
          -  Having an internet access at home and using an email address&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other arthritis than RA&#xD;
&#xD;
          -  To participate to a blind-randomized study to assess RA treatment&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Patient unable to understand the study, unable to give consent&#xD;
&#xD;
          -  Patient deprived of liberty or patient under guardianship&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Patients having difficulty using connected objects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert MAROTTE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hubert MAROTTE, PHD</last_name>
    <phone>0477127649</phone>
    <phone_ext>+33</phone_ext>
    <email>hubert.marotte@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence RANCON</last_name>
    <phone>0477829458</phone>
    <phone_ext>+33</phone_ext>
    <email>florence.rancon@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de Besancon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CLEMENT PRATI, MDPHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Infirmerie Protestante deLyon</name>
      <address>
        <city>Caluire-et-Cuire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>André BASCH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claire TOURNADRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sud</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Athan BAILLET, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GAUDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emmanuelle Dernis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yves Marie PERS, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Orleans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>CARINE SAILLOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jérémie SELLAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille DEPROUW, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims - Hôpital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Hugues SALMON, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hubert MAROTTE, pHD</last_name>
    </contact>
    <investigator>
      <last_name>Hubert Marotte, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent ARNAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adeline RUYSSEN-WITRAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <keyword>synthetic disease modifying antirheumatic drug (csDMARD)</keyword>
  <keyword>biologic disease modifying antirheumatic drug (bDMARD)</keyword>
  <keyword>Machine Learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

